BOOST.AI
25.11.2022 09:02:38 CET | Business Wire | Press release
Boost.ai, a Nordic Capital-backed global leader in conversational AI for enterprises, today announced that Jerry Haywood is joining the company’s executive team as Chief Executive Officer effective December 1, 2022. Haywood brings 20 years of enterprise technology experience with him and has held various sales and senior leadership positions at IBM, Cisco, and Salesforce. He joins Boost.ai from LivePerson, a global technology company that develops conversational commerce and AI software. Haywood will succeed founder and current CEO Lars Ropeid Selsås, who desires to devote more time to product development and innovation.
Selsås, who was actively involved in the selection process, alongside Co-Founder and Chief Commercial Officer Henry Vaage Iversen, and Chief Operating Officer Camilla Gjetvik, stated: “During this time of accelerated digital customer experience transformation, Boost.ai has never been better positioned to become a global category leader in conversational AI. This change in leadership is a natural step in the next growth phase for Boost.ai. Jerry is a strong and experienced visionary leader who can build on the solid foundation created over the last six years, and we are thrilled to have him join us. While it is his outstanding track record that made him a natural candidate for this key leadership role, it was his personality and people-oriented leadership style that impressed us most. He is approachable, humble, and full of energy. A natural leader who can create results while making it a fun ride.”
Vaage Iversen added: “I am very happy that Jerry has agreed to join the Boost.ai team as CEO and I'm glad that we are able to fulfil Lars’ desire to focus even more on what he is most passionate about - the technology needed to fundamentally disrupt the conversational AI category and to continue to provide the best automated customer interaction solution available on the market.”
For the last three years, Haywood has held the role of SVP EMEA at LivePerson, where he led the strategic repositioning of the company in Europe, achieving impressive growth. Prior to LivePerson, Haywood spent eight years at Salesforce, where he headed up Service Cloud first in the UK, and then for the rest of Europe, achieving an increase of over 30% in revenue and bookings year after year.
Haywood said: “I am really excited and honoured to join the Boost.ai team, at a time where the owners and leadership want to accelerate growth while positioning the company as a global category leader in the conversational AI space. Boost.ai is already very familiar to me. I have followed their amazing journey closely and I am convinced that the scale up has what it needs to go all the way. Boost.ai has the best technology available and an amazing team with some of the brightest minds in the industry. I want to thank the founders, the Board of Directors and Nordic Capital for their trust. I can't wait to meet the team across the globe and get started.”
Haywood will balance his time between Stavanger, Norway, where Boost.ai is headquartered, and London, UK, one of Boost.ai’s key markets, where he lives with his wife and three children.
About Boost.ai
Boost.ai specializes in enterprise-grade conversational artificial intelligence (AI). Inventor of the world’s most scalable conversational AI platform, Boost.ai empowers enterprises to automate customer service and internal support channels, enhance human efficiency, and drive revenue with proprietary self-learning AI and a no-code solution that’s quick to deploy, easy to learn and highly scalable. Learn more at boost.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221125005046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom